STOCK TITAN

[Form 4] Incyte Genomics Inc Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

JPMorgan Chase Financial Company LLC is offering $1.08 million of Auto Callable Contingent Interest Notes linked to the common stock of Merck & Co., Inc. (MRK). The unsecured notes price on 2 July 2025, settle on or about 8 July 2025 and mature on 7 January 2027 unless automatically called earlier.

Interest mechanics: Investors receive a Contingent Interest Payment of $9.9167 per $1,000 note (11.90% p.a., paid monthly) for each Review Date on which MRK’s closing price is at least 65 % of the Initial Value ($53.5535). If the price is below that level, the coupon for that period is forfeited.

Automatic call: Beginning with the 9th Review Date (2 Apr 2026), the notes are redeemed at par plus the current coupon if MRK closes at or above the Initial Value ($82.39) on any subsequent Review Date (except the final one). Early call shortens the investment to as little as nine months.

Principal repayment: • If not called and MRK’s Final Value ≥ 65 % of the Initial Value, investors receive par plus the final coupon.
• If the Final Value is < 65 %, repayment is $1,000 + ($1,000 × Stock Return), exposing investors to full downside below the 35% buffer, with potential total loss of principal.

Pricing & fees: The public offering price equals par; affiliated advisory accounts forgo commissions. The estimated value is $978.80 per $1,000, reflecting structuring and hedging costs. Minimum denomination is $1,000; CUSIP 48136EU52.

Key risks highlighted: loss of principal, non-payment of interest, issuer/guarantor credit risk, early-call reinvestment risk, lack of secondary-market liquidity, valuation discount to issue price and limited upside (investors do not participate in any MRK appreciation beyond coupons).

JPMorgan Chase Financial Company LLC offre 1,08 milioni di dollari di Auto Callable Contingent Interest Notes collegati alle azioni ordinarie di Merck & Co., Inc. (MRK). Le note non garantite hanno prezzo il 2 luglio 2025, si regolano intorno al 8 luglio 2025 e scadono il 7 gennaio 2027, salvo richiamo automatico anticipato.

Meccanismo degli interessi: Gli investitori ricevono un pagamento di interesse condizionato di 9,9167 $ per ogni nota da 1.000 $ (11,90% annuo, pagato mensilmente) per ogni data di revisione in cui il prezzo di chiusura di MRK è almeno il 65% del valore iniziale (53,5535 $). Se il prezzo è inferiore a tale soglia, la cedola per quel periodo viene persa.

Richiamo automatico: A partire dalla 9ª data di revisione (2 aprile 2026), le note vengono rimborsate a pari valore più la cedola corrente se MRK chiude al pari o sopra il valore iniziale (82,39 $) in una qualsiasi data di revisione successiva (eccetto l’ultima). Il richiamo anticipato riduce l’investimento a un minimo di nove mesi.

Rimborso del capitale: • Se non richiamate e il valore finale di MRK è ≥ 65% del valore iniziale, gli investitori ricevono il valore nominale più l’ultima cedola.
• Se il valore finale è < 65%, il rimborso è 1.000 $ + (1.000 $ × rendimento azionario), esponendo gli investitori a una perdita totale del capitale sotto la soglia del 35%.

Prezzo e commissioni: Il prezzo di offerta pubblica è pari; i conti consulenziali affiliati rinunciano alle commissioni. Il valore stimato è di 978,80 $ per 1.000 $, riflettendo i costi di strutturazione e copertura. Taglio minimo 1.000 $; CUSIP 48136EU52.

Rischi principali evidenziati: perdita del capitale, mancato pagamento degli interessi, rischio di credito emittente/garante, rischio di reinvestimento da richiamo anticipato, scarsa liquidità sul mercato secondario, sconto di valutazione rispetto al prezzo di emissione e potenziale limitato (gli investitori non partecipano a eventuali apprezzamenti di MRK oltre le cedole).

JPMorgan Chase Financial Company LLC ofrece 1,08 millones de dólares en Auto Callable Contingent Interest Notes vinculados a las acciones comunes de Merck & Co., Inc. (MRK). Los bonos no garantizados se cotizan el 2 de julio de 2025, se liquidan aproximadamente el 8 de julio de 2025 y vencen el 7 de enero de 2027, salvo que se llamen automáticamente antes.

Mecánica de intereses: Los inversores reciben un pago de interés contingente de 9,9167 $ por cada nota de 1.000 $ (11,90% anual, pagado mensualmente) para cada fecha de revisión en la que el precio de cierre de MRK sea al menos el 65% del valor inicial (53,5535 $). Si el precio está por debajo de ese nivel, el cupón de ese periodo se pierde.

Llamada automática: A partir de la 9ª fecha de revisión (2 de abril de 2026), los bonos se redimen a la par más el cupón actual si MRK cierra en o por encima del valor inicial (82,39 $) en cualquier fecha de revisión posterior (excepto la final). La llamada anticipada puede acortar la inversión a tan solo nueve meses.

Reembolso del principal: • Si no se llama y el valor final de MRK ≥ 65% del valor inicial, los inversores reciben el valor nominal más el cupón final.
• Si el valor final es < 65%, el reembolso es 1.000 $ + (1.000 $ × rendimiento de la acción), exponiendo a los inversores a una pérdida total del principal por debajo del umbral del 35%.

Precio y comisiones: El precio de oferta pública es par; las cuentas asesoras afiliadas renuncian a comisiones. El valor estimado es de 978,80 $ por 1.000 $, reflejando costos de estructuración y cobertura. Denominación mínima 1.000 $; CUSIP 48136EU52.

Riesgos clave destacados: pérdida del principal, impago de intereses, riesgo crediticio del emisor/garante, riesgo de reinversión por llamada anticipada, falta de liquidez en el mercado secundario, descuento en valoración respecto al precio de emisión y potencial limitado (los inversores no participan en ninguna apreciación de MRK más allá de los cupones).

JPMorgan Chase Financial Company LLCMerck & Co., Inc. (MRK) 보통주와 연계된 자동 콜 가능 조건부 이자 노트 108만 달러를 제공합니다. 이 무담보 노트는 2025년 7월 2일에 가격이 정해지고, 2025년 7월 8일경에 결제되며, 자동 콜이 없으면 2027년 1월 7일에 만기됩니다.

이자 구조: 투자자는 MRK 종가가 초기 가치($53.5535)의 65% 이상인 각 검토일에 대해 노트 1,000달러당 $9.9167의 조건부 이자 지급(연 11.90%, 매월 지급)을 받습니다. 가격이 이 수준 아래이면 해당 기간의 쿠폰은 지급되지 않습니다.

자동 콜: 9번째 검토일(2026년 4월 2일)부터 MRK가 이후 검토일(최종일 제외)에 초기 가치($82.39) 이상으로 마감하면 노트는 액면가와 현재 쿠폰을 포함해 상환됩니다. 조기 콜 시 투자 기간은 최소 9개월로 단축됩니다.

원금 상환: • 콜되지 않고 MRK의 최종 가치가 초기 가치의 65% 이상이면 투자자는 액면가와 마지막 쿠폰을 받습니다.
• 최종 가치가 65% 미만이면 상환금은 $1,000 + ($1,000 × 주가 수익률)로, 35% 버퍼 아래에서는 원금 전액 손실 위험이 있습니다.

가격 및 수수료: 공개 발행 가격은 액면가이며, 제휴 자문 계좌는 수수료를 포기합니다. 추정 가치는 1,000달러당 $978.80로 구조화 및 헤지 비용이 반영되어 있습니다. 최소 단위는 1,000달러이며, CUSIP은 48136EU52입니다.

주요 위험 요약: 원금 손실, 이자 미지급, 발행자/보증인 신용 위험, 조기 콜 재투자 위험, 2차 시장 유동성 부족, 발행가 대비 평가 할인, 제한된 상승 잠재력(투자자는 쿠폰 이상의 MRK 주가 상승에 참여하지 않음).

JPMorgan Chase Financial Company LLC propose 1,08 million de dollars de Auto Callable Contingent Interest Notes liés aux actions ordinaires de Merck & Co., Inc. (MRK). Les billets non garantis sont prix le 2 juillet 2025, réglés vers le 8 juillet 2025 et arrivent à échéance le 7 janvier 2027, sauf rappel automatique anticipé.

Mécanique des intérêts : Les investisseurs reçoivent un paiement d’intérêt conditionnel de 9,9167 $ par billet de 1 000 $ (11,90 % par an, payé mensuellement) pour chaque date de revue où le cours de clôture de MRK est au moins à 65 % de la valeur initiale (53,5535 $). Si le cours est inférieur, le coupon pour cette période est perdu.

Rappel automatique : À partir de la 9e date de revue (2 avril 2026), les billets sont remboursés à leur valeur nominale plus le coupon courant si MRK clôture à ou au-dessus de la valeur initiale (82,39 $) à toute date de revue ultérieure (sauf la dernière). Un rappel anticipé peut réduire la durée d’investissement à neuf mois.

Remboursement du principal : • Si non rappelés et que la valeur finale de MRK est ≥ 65 % de la valeur initiale, les investisseurs reçoivent la valeur nominale plus le coupon final.
• Si la valeur finale est < 65 %, le remboursement est de 1 000 $ + (1 000 $ × rendement de l’action), exposant les investisseurs à une perte totale du capital en dessous du seuil de 35 %.

Prix et frais : Le prix d’offre publique est à la valeur nominale ; les comptes-conseils affiliés renoncent aux commissions. La valeur estimée est de 978,80 $ par 1 000 $, reflétant les coûts de structuration et de couverture. La coupure minimale est de 1 000 $ ; CUSIP 48136EU52.

Principaux risques soulignés : perte du capital, non-paiement des intérêts, risque de crédit de l’émetteur/garant, risque de réinvestissement lié au rappel anticipé, manque de liquidité sur le marché secondaire, décote de valorisation par rapport au prix d’émission et potentiel limité (les investisseurs ne participent pas à l’appréciation de MRK au-delà des coupons).

JPMorgan Chase Financial Company LLC bietet 1,08 Millionen US-Dollar an Auto Callable Contingent Interest Notes an, die an die Stammaktien von Merck & Co., Inc. (MRK) gekoppelt sind. Die unbesicherten Notes werden am 2. Juli 2025 bepreist, am oder um den 8. Juli 2025 abgewickelt und laufen bis zum 7. Januar 2027, sofern sie nicht vorher automatisch zurückgerufen werden.

Zinsmechanik: Anleger erhalten eine bedingte Zinszahlung von 9,9167 $ pro 1.000-$-Note (11,90% p.a., monatlich gezahlt) für jeden Bewertungstag, an dem der Schlusskurs von MRK mindestens 65% des Anfangswerts (53,5535 $) beträgt. Liegt der Kurs darunter, verfällt der Kupon für diesen Zeitraum.

Automatischer Rückruf: Ab dem 9. Bewertungstag (2. April 2026) werden die Notes zum Nennwert plus dem aktuellen Kupon zurückgezahlt, wenn MRK an einem nachfolgenden Bewertungstag (außer dem letzten) auf oder über dem Anfangswert (82,39 $) schließt. Ein früher Rückruf verkürzt die Anlage auf mindestens neun Monate.

Kapitalrückzahlung: • Wird nicht zurückgerufen und ist der Endwert von MRK ≥ 65% des Anfangswerts, erhalten Anleger den Nennwert plus den letzten Kupon.
• Liegt der Endwert < 65%, erfolgt die Rückzahlung in Höhe von 1.000 $ + (1.000 $ × Aktienrendite), was Anleger einem vollständigen Kapitalverlust unterhalb der 35%-Schwelle aussetzt.

Preisgestaltung & Gebühren: Der öffentliche Ausgabepreis entspricht dem Nennwert; verbundene Beratungskonten verzichten auf Provisionen. Der geschätzte Wert beträgt 978,80 $ pro 1.000 $ und berücksichtigt Strukturierungs- und Absicherungskosten. Mindeststückelung 1.000 $; CUSIP 48136EU52.

Hervorgehobene Hauptrisiken: Kapitalverlust, Nichtzahlung von Zinsen, Emittenten-/Garanten-Kreditrisiko, Reinvestitionsrisiko bei vorzeitiger Rückzahlung, mangelnde Liquidität am Sekundärmarkt, Bewertungsabschlag gegenüber dem Ausgabepreis und begrenztes Aufwärtspotenzial (Anleger partizipieren nicht an Kurssteigerungen von MRK über die Kupons hinaus).

Positive
  • High contingent coupon of 11.90% p.a. if MRK stays above the 65% barrier on observation dates.
  • 35% downside buffer before principal losses begin at maturity.
  • Automatic call provides early return of capital plus coupon if MRK meets the threshold, potentially enhancing annualised yield.
  • Full and unconditional guarantee by JPMorgan Chase & Co., a large investment-grade issuer.
Negative
  • Principal at risk below the 65% trigger; investors could suffer a total loss if MRK falls sharply.
  • Coupons are not guaranteed; any period with MRK under the barrier pays zero interest.
  • Limited upside: returns are capped at cumulative coupons; investors do not benefit from stock appreciation.
  • Liquidity risk: notes are unlisted; resale is subject to dealer discretion and likely below issue price.
  • Estimated value ($978.80) is below issue price, indicating an immediate mark-to-market discount.
  • Early-call reinvestment risk: high-coupon stream may end after nine months if MRK trades above the initial price.

Insights

TL;DR — 11.9 % coupon with 35 % downside buffer; early call likely; limited upside.

The note offers an above-market 11.9% annualised contingent coupon versus MRK equity risk. Investors are protected only down to 65 % of the initial MRK price, after which losses mirror the stock. The automatic-call feature caps duration and total return once MRK trades at or above its initial level after nine months, making the effective yield path-dependent. The issuer’s estimated value is 2.1 % below issue price, signalling an immediate mark-to-market discount. Liquidity is dealer-driven and the notes are unlisted. Overall, the structure suits yield-seeking accounts comfortable with single-stock risk and credit exposure to JPMorgan, but upside is limited to cumulative coupons.

TL;DR — Attractive income, but high idiosyncratic and liquidity risk; neutral impact.

The 35 % buffer appears generous relative to MRK’s historical volatility, yet single-name exposure raises concentration risk. Automatic call can truncate income streams, creating reinvestment challenges in lower-rate environments. The absence of listing plus the internal funding rate discount mean secondary sales could realise material losses. From a portfolio perspective, the product may complement fixed income in a low-rate setting, but sizing should reflect the possibility of 100 % loss if MRK collapses alongside a JPM credit event. Impact on JPM shareholders is negligible; for investors, risk-reward is balanced, hence a neutral rating.

JPMorgan Chase Financial Company LLC offre 1,08 milioni di dollari di Auto Callable Contingent Interest Notes collegati alle azioni ordinarie di Merck & Co., Inc. (MRK). Le note non garantite hanno prezzo il 2 luglio 2025, si regolano intorno al 8 luglio 2025 e scadono il 7 gennaio 2027, salvo richiamo automatico anticipato.

Meccanismo degli interessi: Gli investitori ricevono un pagamento di interesse condizionato di 9,9167 $ per ogni nota da 1.000 $ (11,90% annuo, pagato mensilmente) per ogni data di revisione in cui il prezzo di chiusura di MRK è almeno il 65% del valore iniziale (53,5535 $). Se il prezzo è inferiore a tale soglia, la cedola per quel periodo viene persa.

Richiamo automatico: A partire dalla 9ª data di revisione (2 aprile 2026), le note vengono rimborsate a pari valore più la cedola corrente se MRK chiude al pari o sopra il valore iniziale (82,39 $) in una qualsiasi data di revisione successiva (eccetto l’ultima). Il richiamo anticipato riduce l’investimento a un minimo di nove mesi.

Rimborso del capitale: • Se non richiamate e il valore finale di MRK è ≥ 65% del valore iniziale, gli investitori ricevono il valore nominale più l’ultima cedola.
• Se il valore finale è < 65%, il rimborso è 1.000 $ + (1.000 $ × rendimento azionario), esponendo gli investitori a una perdita totale del capitale sotto la soglia del 35%.

Prezzo e commissioni: Il prezzo di offerta pubblica è pari; i conti consulenziali affiliati rinunciano alle commissioni. Il valore stimato è di 978,80 $ per 1.000 $, riflettendo i costi di strutturazione e copertura. Taglio minimo 1.000 $; CUSIP 48136EU52.

Rischi principali evidenziati: perdita del capitale, mancato pagamento degli interessi, rischio di credito emittente/garante, rischio di reinvestimento da richiamo anticipato, scarsa liquidità sul mercato secondario, sconto di valutazione rispetto al prezzo di emissione e potenziale limitato (gli investitori non partecipano a eventuali apprezzamenti di MRK oltre le cedole).

JPMorgan Chase Financial Company LLC ofrece 1,08 millones de dólares en Auto Callable Contingent Interest Notes vinculados a las acciones comunes de Merck & Co., Inc. (MRK). Los bonos no garantizados se cotizan el 2 de julio de 2025, se liquidan aproximadamente el 8 de julio de 2025 y vencen el 7 de enero de 2027, salvo que se llamen automáticamente antes.

Mecánica de intereses: Los inversores reciben un pago de interés contingente de 9,9167 $ por cada nota de 1.000 $ (11,90% anual, pagado mensualmente) para cada fecha de revisión en la que el precio de cierre de MRK sea al menos el 65% del valor inicial (53,5535 $). Si el precio está por debajo de ese nivel, el cupón de ese periodo se pierde.

Llamada automática: A partir de la 9ª fecha de revisión (2 de abril de 2026), los bonos se redimen a la par más el cupón actual si MRK cierra en o por encima del valor inicial (82,39 $) en cualquier fecha de revisión posterior (excepto la final). La llamada anticipada puede acortar la inversión a tan solo nueve meses.

Reembolso del principal: • Si no se llama y el valor final de MRK ≥ 65% del valor inicial, los inversores reciben el valor nominal más el cupón final.
• Si el valor final es < 65%, el reembolso es 1.000 $ + (1.000 $ × rendimiento de la acción), exponiendo a los inversores a una pérdida total del principal por debajo del umbral del 35%.

Precio y comisiones: El precio de oferta pública es par; las cuentas asesoras afiliadas renuncian a comisiones. El valor estimado es de 978,80 $ por 1.000 $, reflejando costos de estructuración y cobertura. Denominación mínima 1.000 $; CUSIP 48136EU52.

Riesgos clave destacados: pérdida del principal, impago de intereses, riesgo crediticio del emisor/garante, riesgo de reinversión por llamada anticipada, falta de liquidez en el mercado secundario, descuento en valoración respecto al precio de emisión y potencial limitado (los inversores no participan en ninguna apreciación de MRK más allá de los cupones).

JPMorgan Chase Financial Company LLCMerck & Co., Inc. (MRK) 보통주와 연계된 자동 콜 가능 조건부 이자 노트 108만 달러를 제공합니다. 이 무담보 노트는 2025년 7월 2일에 가격이 정해지고, 2025년 7월 8일경에 결제되며, 자동 콜이 없으면 2027년 1월 7일에 만기됩니다.

이자 구조: 투자자는 MRK 종가가 초기 가치($53.5535)의 65% 이상인 각 검토일에 대해 노트 1,000달러당 $9.9167의 조건부 이자 지급(연 11.90%, 매월 지급)을 받습니다. 가격이 이 수준 아래이면 해당 기간의 쿠폰은 지급되지 않습니다.

자동 콜: 9번째 검토일(2026년 4월 2일)부터 MRK가 이후 검토일(최종일 제외)에 초기 가치($82.39) 이상으로 마감하면 노트는 액면가와 현재 쿠폰을 포함해 상환됩니다. 조기 콜 시 투자 기간은 최소 9개월로 단축됩니다.

원금 상환: • 콜되지 않고 MRK의 최종 가치가 초기 가치의 65% 이상이면 투자자는 액면가와 마지막 쿠폰을 받습니다.
• 최종 가치가 65% 미만이면 상환금은 $1,000 + ($1,000 × 주가 수익률)로, 35% 버퍼 아래에서는 원금 전액 손실 위험이 있습니다.

가격 및 수수료: 공개 발행 가격은 액면가이며, 제휴 자문 계좌는 수수료를 포기합니다. 추정 가치는 1,000달러당 $978.80로 구조화 및 헤지 비용이 반영되어 있습니다. 최소 단위는 1,000달러이며, CUSIP은 48136EU52입니다.

주요 위험 요약: 원금 손실, 이자 미지급, 발행자/보증인 신용 위험, 조기 콜 재투자 위험, 2차 시장 유동성 부족, 발행가 대비 평가 할인, 제한된 상승 잠재력(투자자는 쿠폰 이상의 MRK 주가 상승에 참여하지 않음).

JPMorgan Chase Financial Company LLC propose 1,08 million de dollars de Auto Callable Contingent Interest Notes liés aux actions ordinaires de Merck & Co., Inc. (MRK). Les billets non garantis sont prix le 2 juillet 2025, réglés vers le 8 juillet 2025 et arrivent à échéance le 7 janvier 2027, sauf rappel automatique anticipé.

Mécanique des intérêts : Les investisseurs reçoivent un paiement d’intérêt conditionnel de 9,9167 $ par billet de 1 000 $ (11,90 % par an, payé mensuellement) pour chaque date de revue où le cours de clôture de MRK est au moins à 65 % de la valeur initiale (53,5535 $). Si le cours est inférieur, le coupon pour cette période est perdu.

Rappel automatique : À partir de la 9e date de revue (2 avril 2026), les billets sont remboursés à leur valeur nominale plus le coupon courant si MRK clôture à ou au-dessus de la valeur initiale (82,39 $) à toute date de revue ultérieure (sauf la dernière). Un rappel anticipé peut réduire la durée d’investissement à neuf mois.

Remboursement du principal : • Si non rappelés et que la valeur finale de MRK est ≥ 65 % de la valeur initiale, les investisseurs reçoivent la valeur nominale plus le coupon final.
• Si la valeur finale est < 65 %, le remboursement est de 1 000 $ + (1 000 $ × rendement de l’action), exposant les investisseurs à une perte totale du capital en dessous du seuil de 35 %.

Prix et frais : Le prix d’offre publique est à la valeur nominale ; les comptes-conseils affiliés renoncent aux commissions. La valeur estimée est de 978,80 $ par 1 000 $, reflétant les coûts de structuration et de couverture. La coupure minimale est de 1 000 $ ; CUSIP 48136EU52.

Principaux risques soulignés : perte du capital, non-paiement des intérêts, risque de crédit de l’émetteur/garant, risque de réinvestissement lié au rappel anticipé, manque de liquidité sur le marché secondaire, décote de valorisation par rapport au prix d’émission et potentiel limité (les investisseurs ne participent pas à l’appréciation de MRK au-delà des coupons).

JPMorgan Chase Financial Company LLC bietet 1,08 Millionen US-Dollar an Auto Callable Contingent Interest Notes an, die an die Stammaktien von Merck & Co., Inc. (MRK) gekoppelt sind. Die unbesicherten Notes werden am 2. Juli 2025 bepreist, am oder um den 8. Juli 2025 abgewickelt und laufen bis zum 7. Januar 2027, sofern sie nicht vorher automatisch zurückgerufen werden.

Zinsmechanik: Anleger erhalten eine bedingte Zinszahlung von 9,9167 $ pro 1.000-$-Note (11,90% p.a., monatlich gezahlt) für jeden Bewertungstag, an dem der Schlusskurs von MRK mindestens 65% des Anfangswerts (53,5535 $) beträgt. Liegt der Kurs darunter, verfällt der Kupon für diesen Zeitraum.

Automatischer Rückruf: Ab dem 9. Bewertungstag (2. April 2026) werden die Notes zum Nennwert plus dem aktuellen Kupon zurückgezahlt, wenn MRK an einem nachfolgenden Bewertungstag (außer dem letzten) auf oder über dem Anfangswert (82,39 $) schließt. Ein früher Rückruf verkürzt die Anlage auf mindestens neun Monate.

Kapitalrückzahlung: • Wird nicht zurückgerufen und ist der Endwert von MRK ≥ 65% des Anfangswerts, erhalten Anleger den Nennwert plus den letzten Kupon.
• Liegt der Endwert < 65%, erfolgt die Rückzahlung in Höhe von 1.000 $ + (1.000 $ × Aktienrendite), was Anleger einem vollständigen Kapitalverlust unterhalb der 35%-Schwelle aussetzt.

Preisgestaltung & Gebühren: Der öffentliche Ausgabepreis entspricht dem Nennwert; verbundene Beratungskonten verzichten auf Provisionen. Der geschätzte Wert beträgt 978,80 $ pro 1.000 $ und berücksichtigt Strukturierungs- und Absicherungskosten. Mindeststückelung 1.000 $; CUSIP 48136EU52.

Hervorgehobene Hauptrisiken: Kapitalverlust, Nichtzahlung von Zinsen, Emittenten-/Garanten-Kreditrisiko, Reinvestitionsrisiko bei vorzeitiger Rückzahlung, mangelnde Liquidität am Sekundärmarkt, Bewertungsabschlag gegenüber dem Ausgabepreis und begrenztes Aufwärtspotenzial (Anleger partizipieren nicht an Kurssteigerungen von MRK über die Kupons hinaus).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hoppenot Herve

(Last) (First) (Middle)
1801 AUGUSTINE CUT-OFF

(Street)
WILMINGTON DE 19803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Special Advisor to the CEO
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/02/2025 F 42,769(1) D $68.17 526,820(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.
2. This includes an aggregate of 94,538 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
Remarks:
/s/ Elizabeth Feeney, Attorney-In-Fact 07/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What is the contingent interest rate on the JPM Auto Callable Notes linked to MRK?

The notes pay a contingent coupon of 11.90% per annum (0.99167% monthly) when the interest barrier condition is met.

When can the JPM notes be automatically called?

Automatic call can occur on any Review Date from 2 April 2026 onward if MRK closes at or above the $82.39 Initial Value.

How much principal protection do investors have?

A 35% buffer exists: if MRK’s final price is ≥ 65% of the Initial Value, principal is repaid; otherwise losses match the stock’s decline.

What is the estimated value versus the price to public?

The estimated value is $978.80 per $1,000 note, about 2.1% below the $1,000 offer price.

Are the notes listed on an exchange?

No. The notes will not be listed; liquidity depends on bids from J.P. Morgan Securities LLC.

Do investors receive Merck dividends through the notes?

No. Dividends on MRK are not passed through; investors only receive potential contingent coupons.
Incyte Corp

NASDAQ:INCY

INCY Rankings

INCY Latest News

INCY Latest SEC Filings

INCY Stock Data

13.62B
189.32M
1.99%
96.76%
3.02%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON